InVivo Therapeutics (NVIVQ) 10-K 17 Mar 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 05, 2014	Jun. 28, 2013
Document and Entity Information	'	'	'
Entity Registrant Name	'INVIVO THERAPEUTICS HOLDINGS CORP.	'	'
Entity Central Index Key	'0001292519	'	'
Document Type	'10-K	'	'
Document Period End Date	31-Dec-13	'	'
Amendment Flag	'false	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Filer Category	'Accelerated Filer	'	'
Entity Public Float	'	'	$238,670,234
Entity Common Stock, Shares Outstanding	'	78,994,064	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current assets:	'	'
Cash and cash equivalents	$13,980,321	$12,825,090
Restricted cash	601,471	601,351
Prepaid expenses and other current assets	20,087	143,867
Total current assets	14,601,879	13,570,308
Property and equipment, net	2,337,210	2,311,942
Other assets	157,355	179,415
Total assets	17,096,444	16,061,665
Current liabilities:	'	'
Accounts payable	899,260	1,152,550
Note payable-current portion	73,987	'
Capital lease payable-current portion	2,799	32,606
Derivative warrant liability	0	14,584,818
Accrued expenses	1,292,185	1,021,275
Total current liabilities	2,268,231	16,791,249
Loan payable	1,920,000	1,578,000
Note payable-less current portion	18,497	'
Capital lease payable-less current portion	'	2,799
Total liabilities	4,206,728	18,372,048
Commitments and contingencies	'	'
Stockholders' equity (deficit):	'	'
Common stock, $0.00001 par value, authorized 200,000,000 shares; issued and outstanding 78,773,736 and 65,881,122 shares at December 31 2013 and 2012, respectively	788	659
Additional paid-in capital	94,798,231	40,842,339
Deficit accumulated during the development stage	-81,909,303	-43,153,381
Total stockholders' equity (deficit)	12,889,716	-2,310,383
Total liabilities and stockholders' equity (deficit)	$17,096,444	$16,061,665

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Consolidated Balance Sheets	'	'
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, authorized	200,000,000	200,000,000
Common stock, issued	78,773,736	65,881,122
Common stock, outstanding	78,773,736	65,881,122

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended			97 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013
Operating expenses:	'	'	'	'
Research and development	$10,533,004	$6,375,795	$4,102,847	$25,792,633
General and administrative	8,472,197	6,403,656	4,555,872	23,127,390
Total operating expenses	19,005,201	12,779,451	8,658,719	48,920,023
Operating loss	-19,005,201	-12,779,451	-8,658,719	-48,920,023
Other income (expense):	'	'	'	'
Other income	'	'	'	383,000
Interest income	15,279	35,184	8,759	70,512
Interest expense	-129,902	-71,726	-12,676	-1,267,959
Modification of warrants	-764,769	'	'	-764,769
Derivatives gain (loss)	-18,871,329	17,479,674	-26,065,579	-31,409,816
Other income (expense), net	-19,750,721	17,443,132	-26,069,496	-32,989,032
Net income (loss)	($38,755,922)	$4,663,681	($34,728,215)	($81,909,055)
Net income (loss) per share, basic (in dollars per share)	($0.52)	$0.07	($0.67)	($2.04)
Net income (loss) per share, diluted (in dollars per share)	($0.52)	$0.06	($0.67)	($2.04)
Weighted average number of common shares outstanding, basic (in shares)	73,991,686	63,226,899	51,894,871	40,121,647
Weighted average number of common shares outstanding, diluted (in shares)	73,991,686	71,919,419	51,894,871	40,121,647

Consolidated_Statements_of_Cha

Consolidated Statements of Changes in Stockholders' Equity (Deficit) (USD $)

Total

Convertible Notes Payable and Accrued Interest

Private placement

Private placement

Public offering

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Additional Paid-in Capital

Additional Paid-in Capital

Additional Paid-in Capital

Additional Paid-in Capital

Additional Paid-in Capital

Deficit Accumulated During the Development Stage

Deficit Accumulated During the Development Stage

Bridge Notes Payable

Convertible Notes Payable and Accrued Interest

Founders stock

Private placement

Private placement

Public offering

Convertible Notes Payable and Accrued Interest

Private placement

Private placement

Public offering

Founders stock

Bridge Notes Payable

Bridge Notes Payable

Beginning Balance at Nov. 28, 2005

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based compensation expense

$18,347

'

'

'

'

'

'

'

'

'

'

$18,347

'

'

'

'

'

'

Issuance of founders stock

'

'

'

'

'

'

'

248

'

'

'

'

'

'

'

'

'

-248

Issuance of founders stock (in shares)

'

'

'

'

'

'

'

24,787,080

'

'

'

'

'

'

'

'

'

'

Net income (loss)

-1,097,702

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-1,097,702

'

Closing Balance at Dec. 31, 2007

-1,079,355

'

'

'

'

248

'

'

'

'

'

18,347

'

'

'

'

-1,097,950

'

Ending Balance, (in shares) at Dec. 31, 2007

'

'

'

'

'

24,787,080

'

'

'

'

'

'

'

'

'

'

'

'

Share-based compensation expense

24,526

'

'

'

'

'

'

'

'

'

'

24,526

'

'

'

'

'

'

Net income (loss)

-1,564,069

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-1,564,069

'

Closing Balance at Dec. 31, 2008

-2,618,898

'

'

'

'

248

'

'

'

'

'

42,873

'

'

'

'

-2,662,019

'

Ending Balance, (in shares) at Dec. 31, 2008

'

'

'

'

'

24,787,080

'

'

'

'

'

'

'

'

'

'

'

'

Share-based compensation expense

171,059

'

'

'

'

'

'

'

'

'

'

171,059

'

'

'

'

'

'

Conversion of convertible securities

'

1,344,366

'

'

'

'

15

'

'

'

'

'

1,344,351

'

'

'

'

'

Conversion of convertible securities (in shares)

'

'

'

'

'

'

1,472,435

'

'

'

'

'

'

'

'

'

'

'

Net income (loss)

-2,515,878

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-2,515,878

'

Closing Balance at Dec. 31, 2009

-3,619,351

'

'

'

'

263

'

'

'

'

'

1,558,283

'

'

'

'

-5,177,897

'

Beginning Balance, (in shares) at Dec. 31, 2009

'

'

'

'

'

26,259,515

'

'

'

'

'

'

'

'

'

'

'

'

Share-based compensation expense

664,908

'

'

'

'

'

'

'

'

'

'

664,908

'

'

'

'

'

'

Issuance of stock

1,000,000

'

3,907,404

'

'

10

'

'

130

'

'

990,990

'

3,907,274

'

'

'

'

Issuance of stock (in shares)

'

'

'

'

'

1,095,258

'

'

12,995,403

'

'

'

'

'

'

'

'

'

Conversion of convertible securities

'

3,328,128

'

504,597

'

'

38

'

'

5

'

'

3,328,090

'

504,592

'

'

'

Conversion of convertible securities (in shares)

'

'

'

'

'

'

3,792,417

'

'

504,597

'

'

'

'

'

'

'

'

Issuance of common stock in reverse merger

'

'

'

'

'

70

'

'

'

'

'

-70

'

'

'

'

'

'

Issuance of common stock in reverse merger (in shares)

'

'

'

'

'

6,999,981

'

'

'

'

'

'

'

'

'

'

'

'

Beneficial conversion feature on notes payable

'

272,762

'

'

'

'

'

'

'

'

'

'

272,762

'

'

'

'

'

Net income (loss)

-7,910,950

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-7,910,950

'

Closing Balance at Dec. 31, 2010

-1,852,502

'

'

'

'

516

'

'

'

'

'

11,235,829

'

'

'

'

-13,088,847

'

Ending Balance, (in shares) at Dec. 31, 2010

'

'

'

'

'

51,647,171

'

'

'

'

'

'

'

'

'

'

'

'

Share-based compensation expense

921,512

'

'

'

'

'

'

'

'

'

'

921,512

'

'

'

'

'

'

Issuance of stock

'

'

2,000,000

'

'

'

'

'

10

'

'

'

'

1,999,990

'

'

'

'

Issuance of stock (in shares)

'

'

'

'

'

'

'

'

980,392

'

'

'

'

'

'

'

'

'

Issuance of stock for services (in dollars)

209,450

'

'

'

'

2

'

'

'

'

'

209,448

'

'

'

'

'

'

Issuance of stock for services (in shares)

'

'

'

'

'

215,000

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock upon exercise of warrants

988,374

'

'

'

'

7

'

'

'

'

'

988,367

'

'

'

'

'

'

Issuance of common stock upon exercise of warrants (in shares)

'

'

'

'

'

734,329

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock upon exercise of stock options

10,435

'

'

'

'

2

'

'

'

'

'

10,433

'

'

'

'

'

'

Issuance of common stock upon exercise of stock options (in shares)

'

'

'

'

'

143,731

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock to 401(k) plan (in dollars)

41,662

'

'

'

'

1

'

'

'

'

'

41,661

'

'

'

'

'

'

Issuance of common stock to 401(k) plan (in shares)

'

'

'

'

'

39,848

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of warrants issued for services

10,051

'

'

'

'

'

'

'

'

'

'

10,051

'

'

'

'

'

'

Fair value of derivative warrant liability reclassified to additional paid-in capital

1,239,539

'

'

'

'

'

'

'

'

'

'

1,239,539

'

'

'

'

'

'

Net income (loss)

-34,728,215

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-34,728,215

'

Closing Balance at Dec. 31, 2011

-31,159,694

'

'

'

'

538

'

'

'

'

'

16,656,830

'

'

'

'

-47,817,062

'

Ending Balance, (in shares) at Dec. 31, 2011

'

'

'

'

'

53,760,471

'

'

'

'

'

'

'

'

'

'

'

'

Beginning Balance at Sep. 30, 2011

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock upon exercise of warrants (in shares)

'

'

'

'

'

734,329

'

'

'

'

'

'

'

'

'

'

'

'

Closing Balance at Dec. 31, 2011

-31,159,694

'

'

'

'

538

'

'

'

'

'

16,656,830

'

'

'

'

-47,817,062

'

Ending Balance, (in shares) at Dec. 31, 2011

'

'

'

'

'

53,760,471

'

'

'

'

'

'

'

'

'

'

'

'

Share-based compensation expense

1,232,959

'

'

'

'

'

'

'

'

'

'

1,232,959

'

'

'

'

'

'

Issuance of stock

'

'

'

'

18,155,043

'

'

'

'

'

95

'

'

'

'

18,154,948

'

'

Issuance of stock (in shares)

'

'

'

'

'

'

'

'

'

'

9,523,810

'

'

'

'

'

'

'

Issuance of stock for services (in dollars)

24,750

'

'

'

'

'

'

'

'

'

'

24,750

'

'

'

'

'

'

Issuance of stock for services (in shares)

'

'

'

'

'

15,000

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock upon exercise of warrants

1,129,095

'

'

'

'

18

'

'

'

'

'

1,129,077

'

'

'

'

'

'

Issuance of common stock upon exercise of warrants (in shares)

'

'

'

'

'

1,779,716

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock upon exercise of stock options

111,605

'

'

'

'

8

'

'

'

'

'

111,597

'

'

'

'

'

'

Issuance of common stock upon exercise of stock options (in shares)

'

'

'

'

'

755,020

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock to 401(k) plan (in dollars)

91,524

'

'

'

'

'

'

'

'

'

'

91,524

'

'

'

'

'

'

Issuance of common stock to 401(k) plan (in shares)

'

'

'

'

'

47,105

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of warrants issued for services

31,916

'

'

'

'

'

'

'

'

'

'

31,916

'

'

'

'

'

'

Fair value of derivative warrant liability reclassified to additional paid-in capital

3,408,738

'

'

'

'

'

'

'

'

'

'

3,408,738

'

'

'

'

'

'

Net income (loss)

4,663,681

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,663,681

'

Closing Balance at Dec. 31, 2012

-2,310,383

'

'

'

'

659

'

'

'

'

'

40,842,339

'

'

'

'

-43,153,381

'

Ending Balance, (in shares) at Dec. 31, 2012

'

'

'

'

'

65,881,122

'

'

'

'

'

'

'

'

'

'

'

'

Share-based compensation expense

3,135,646

'

'

'

'

'

'

'

'

'

'

3,135,646

'

'

'

'

'

'

Issuance of common stock upon exercise of warrants

15,952,107

'

'

'

'

122

'

'

'

'

'

15,951,985

'

'

'

'

'

'

Issuance of common stock upon exercise of warrants (in shares)

'

'

'

'

'

12,224,846

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock upon exercise of stock options

455,550

'

'

'

'

6

'

'

'

'

'

455,544

'

'

'

'

'

'

Issuance of common stock upon exercise of stock options (in shares)

'

'

'

'

'

588,884

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock to 401(k) plan (in dollars)

191,802

'

'

'

'

1

'

'

'

'

'

191,801

'

'

'

'

'

'

Issuance of common stock to 401(k) plan (in shares)

'

'

'

'

'

78,884

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of derivative warrant liability reclassified to additional paid-in capital

33,456,147

'

'

'

'

'

'

'

'

'

'

33,456,147

'

'

'

'

'

'

Incremental fair value from warrant modification

764,769

'

'

'

'

'

'

'

'

'

'

764,769

'

'

'

'

'

'

Net income (loss)

-38,755,922

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-38,755,922

'

Closing Balance at Dec. 31, 2013

$12,889,716

'

'

'

'

$788

'

'

'

'

'

$94,798,231

'

'

'

'

($81,909,303)

'

Ending Balance, (in shares) at Dec. 31, 2013

'

'

'

'

'

78,773,736

'

'

'

'

'

'

'

'

'

'

'

'

Consolidated_Statements_of_Cha1

Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Parenthetical) (Private placement, USD $)	12 Months Ended
	Dec. 31, 2010
Private placement	'
Issuance of common stock in private placement, stock issuance costs	$2,072,117
Issuance of common stock in private placement, non-stock issuance costs	$5,369,570

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended			97 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013
Cash flows from operating activities:	'	'	'	'
Net income (loss)	($38,755,922)	$4,663,681	($34,728,215)	($81,909,055)
Adjustments to reconcile net income (loss) to net cash used in operating activities:	'	'	'	'
Depreciation and amortization expense	740,692	366,893	144,662	1,345,212
Non-cash derivative (gain) losses	18,871,329	-17,479,674	26,065,579	31,409,816
Non-cash interest expense	'	21,870	'	984,704
Non-cash loss from modification of warrants	764,769	'	'	764,769
Common stock issued to 401(k) plan	191,802	91,524	41,662	324,988
Common stock issued for services	'	24,750	209,451	234,201
Share-based compensation expense	3,135,646	1,232,959	921,512	6,168,957
Changes in operating assets and liabilities:	'	'	'	'
Restricted cash	-120	-53,468	-547,883	-601,471
Prepaid expenses and other current assets	123,780	-60,575	-12,805	-30,766
Other assets	4,560	'	-125,000	-195,440
Accounts payable	-253,290	585,355	230,250	899,260
Accrued interest payable	'	'	'	-15,256
Accrued expenses	270,910	402,906	370,822	1,292,185
Net cash used in operating activities	-14,905,844	-10,203,779	-7,429,965	-39,327,896
Cash flows from investing activities:	'	'	'	'
Purchases of property and equipment	-748,460	-2,140,853	-278,923	-3,520,021
Net cash used in investing activities	-748,460	-2,140,853	-278,923	-3,520,021
Cash flows from financing activities:	'	'	'	'
Proceeds from issuance of note payable	149,768	'	'	149,768
Repayment of note payable	-57,284	'	'	-57,284
Proceeds from issuance of convertible notes payable	'	'	'	4,181,000
Proceeds from convertible bridge notes	'	'	'	500,000
Principal payments on capital lease obligation	-32,606	-33,361	-24,774	-90,741
Proceeds from loans payable	342,000	1,747,000	151,733	2,240,733
Repayment of loans payable	'	-303,372	-17,361	-320,733
Proceeds from issuance of common stock and warrants	16,407,657	19,395,743	2,998,808	50,225,495
Net cash provided by financing activities	16,809,535	20,806,010	3,108,406	56,828,238
Increase (Decrease) in cash and cash equivalents	1,155,231	8,461,378	-4,600,482	13,980,321
Cash and cash equivalents at beginning of period	12,825,090	4,363,712	8,964,194	'
Cash and cash equivalents at end of period	13,980,321	12,825,090	4,363,712	13,980,321
Supplemental disclosure of cash flow information and non-cash transactions:	'	'	'	'
Cash paid for interest	125,342	49,862	8,530	281,251
Conversion of convertible notes payable and accrued interest into common stock	'	'	'	4,672,484
Conversion of convertible bridge note payable and accrued interest into common stock	'	'	'	504,597
Asset acquired through capital lease obligation	'	'	93,540	93,540
Beneficial conversion feature on convertible and bridge notes payable	'	'	'	134,410
Fair value of warrants issued with bridge notes payable	'	'	'	178,726
Fair value of warrants issued in connection with loan agreement	'	31,916	10,051	41,967
Issuance of founders shares	'	'	'	248
Reclassification of derivative warrant liability to additional paid-in capital	$33,456,147	$3,408,738	$1,239,539	$38,104,424

NATURE_OF_OPERATIONS_AND_GOING

NATURE OF OPERATIONS AND GOING CONCERN	12 Months Ended
	Dec. 31, 2013
NATURE OF OPERATIONS AND GOING CONCERN	'
NATURE OF OPERATIONS AND GOING CONCERN	'
	1. NATURE OF OPERATIONS AND GOING CONCERN
	Business
	InVivo Therapeutics Corporation ("InVivo") was incorporated on November 28, 2005 under the laws of the State of Delaware. We develop novel biomaterial technologies for the treatment of spinal cord injuries and hydrogels for therapeutics delivery. Our proprietary technologies incorporate intellectual property licensed under an exclusive, world-wide license from Children's Medical Center Corporation ("CMCC") and the Massachusetts Institute of Technology ("MIT"), and intellectual property that has been developed internally, including in collaboration with our advisors and partners.
	Since its inception, InVivo has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, acquiring operating assets and raising capital. Accordingly, InVivo is considered to be in the development stage.
	Going Concern
	The accompanying financial statements have been prepared on a basis that assumes that the Company will continue as a going concern and that contemplates the continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has incurred losses since inception in devoting substantially all of its efforts toward research and development and has an accumulated loss of $81,909,055 at December 31, 2013. During the year ended December 31, 2013, the Company generated a net loss of $38,755,922, used cash in operations of $14,905,844 and the Company expects that it will continue to generate operating losses for the foreseeable future. The Company believes that its cash balance at December 31, 2013 of $13,980,321 is adequate to fund operations at budgeted levels through October of 2014. The Company's ability to execute its operating plan beyond October of 2014 depends on its ability to obtain additional funding via the sale of equity and/or debt securities, a strategic transaction or otherwise. The Company plans to continue to actively pursue financing alternatives, but there can be no assurance that it will obtain the necessary funding. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.
	Reverse Merger
	On October 26, 2010 InVivo completed a reverse merger transaction (the "Merger") with InVivo Therapeutics Holdings Corp. (formerly Design Source, Inc.) ("ITHC"), a publicly traded company incorporated under the laws of the State of Nevada. InVivo became a wholly owned subsidiary of ITHC, which continues to operate the business of InVivo. As part of the Merger, ITHC issued 31,147,190 shares of its Common Stock to the holders of InVivo common stock on October 26, 2010 in exchange for the 2,261,862 outstanding common shares of InVivo and also issued 500,000 shares to its legal counsel in consideration for legal services provided. All share and per share amounts presented in these consolidated financial statements have been retroactively restated to reflect the 13.7706 to 1 exchange ratio of InVivo shares for ITHC shares in the Merger. Immediately prior to the Merger, ITHC had 6,999,981 shares of Common Stock outstanding.
	The Merger was accounted for as a "reverse merger," and InVivo is deemed to be the accounting acquirer. The Merger was recorded as a reverse recapitalization, equivalent to the issuance of common stock by InVivo for the net monetary assets of ITHC accompanied by a recapitalization. At the date of the Merger, the 6,999,981 outstanding ITHC shares were reflected as an issuance of InVivo common stock to the prior shareholders of ITHC. ITHC had no net monetary assets as of the Merger so this issuance was recorded as a reclassification between additional paid-in capital and par value of Common Stock.
	The historical consolidated financial statements are those of InVivo as the accounting acquirer. The post-merger combination of ITHC and InVivo is referred to throughout these notes to consolidated financial statements as the "Company." Subsequent to the Merger, the Company completed three closings as part of a private placement.

SIGNIFICANT_ACCOUNTING_POLICIE

SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2013
SIGNIFICANT ACCOUNTING POLICIES	'
SIGNIFICANT ACCOUNTING POLICIES	'
	2. SIGNIFICANT ACCOUNTING POLICIES
	A summary of the significant accounting policies followed by the Company in the preparation of the financial statements is as follows:
	Use of estimates
	The process of preparing financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and changes in estimates may occur.
	Principles of consolidation
	The consolidated financial statements include the accounts of InVivo Therapeutics Holdings Corp. and its wholly-owned subsidiary, InVivo Therapeutics Corporation. All significant intercompany balances and transactions have been eliminated in consolidation.
	Cash and cash equivalents
	The Company considers only those investments which are highly liquid, readily convertible to cash, and that mature within three months from date of purchase to be cash equivalents. Marketable investments are those with original maturities in excess of three months.
	At December 31, 2013 and 2012, cash equivalents were comprised of money market funds. The Company had no marketable investments at December 31, 2013 and 2012.
	Cash and cash equivalents consist of the following:
		December 31,
		2013		2012
	Cash on deposit	$	219,378	$	209,380
	Money market fund		13,760,943		12,615,710
	Total cash and cash equivalents	$	13,980,321	$	12,825,090
	Restricted cash
	Restricted cash of $601,471 represents a $290,106 security deposit related to the Company's credit card account, and a $311,365 standby letter of credit in favor of a landlord (see Note 17).
	Financial instruments
	The carrying amounts reported in the consolidated balance sheet for cash and cash equivalents and accounts payable approximate fair value based on the short-term nature of these instruments. The carrying value of note and loans payable approximates their fair value due to the market terms.
	Property and equipment
	Property and equipment are carried at cost. Depreciation expense is provided over the estimated useful lives of the assets using the straight-line method. A summary of the estimated useful lives is as follows:
	Classification	Estimated Useful Life
	Computer hardware	5 years
	Software	3 years
	Office furniture and equipment	5 years
	Research and lab equipment	5 years
	Leasehold improvements	Remaining Life of Lease
	Depreciation expense for the years ended December 31, 2013, 2012, and 2011 was $723,192, $349,393, and $132,162 respectively. Maintenance and repairs are charged to expense as incurred, while any additions or improvements are capitalized.
	Research and development expenses
	Costs incurred for research and development are expensed as incurred.
	Concentrations of credit risk
	The Company has no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other hedging arrangements. The Company may from time to time have cash in banks in excess of FDIC insurance limits.
	Segment information
	Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision making group, in making decisions regarding resource allocation and assessing performance. To date, the Company has viewed its operations and manages its business as principally one operating segment, which is developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. As of December 31, 2013 and 2012, all of the Company's assets were located in the United States.
	Income taxes
	For federal and state income taxes, deferred tax assets and liabilities are recognized based upon temporary differences between the financial statement and the tax basis of assets and liabilities. Deferred income taxes are based upon prescribed rates and enacted laws applicable to periods in which differences are expected to reverse. A valuation allowance is recorded when it is more likely than not that some portion or all of the deferred tax assets will not be realized. Accordingly, the Company provides a valuation allowance, if necessary, to reduce deferred tax assets to amounts that are realizable. Tax positions taken or expected to be taken in the course of preparing the Company's tax returns are required to be evaluated to determine whether the tax positions are "more-likely-than-not" of being sustained by the applicable tax authority.
	Tax positions not deemed to meet a more-likely-than-not threshold would be recorded as a tax expense in the current year. There were no uncertain tax positions that require accrual or disclosure to the financial statements as of December 31, 2013 or 2012. Tax years subsequent to 2009 remain open to examination by U.S. federal and state tax authorities.
	Impairment of long-lived assets
	The Company continually monitors events and changes in circumstances that could indicate that carrying amounts of long-lived assets may not be recoverable. An impairment loss is recognized when expected cash flows are less than an asset's carrying value. Accordingly, when indicators of impairment are present, the Company evaluates the carrying value of such assets in relation to the operating performance and future undiscounted cash flows of the underlying assets. The Company's policy is to record an impairment loss when it is determined that the carrying value of the asset may not be recoverable. No impairment charges were recorded for the years ended December 31, 2013, 2012 and 2011.
	Share-based payments
	The Company recognizes compensation costs resulting from the issuance of stock-based awards to employees, non-employees and directors as an expense in the statement of operations over the service period based on a measurement of fair value for each stock-based award. The fair value of each option grant is estimated as of the date of grant using the Black-Scholes option-pricing model. The fair value is amortized as compensation cost on a straight-line basis over the requisite service period of the awards, which is generally the vesting period. Due to its limited operating history, limited number of sales of its Common Stock and limited history of its shares being publicly traded, the Company estimates its volatility in consideration of a number of factors including the volatility of comparable public companies.
	Derivative instruments
	The Company generally does not use derivative instruments to hedge exposures to cash-flow or market risks; however, certain warrants to purchase Common Stock that do not meet the requirements for classification as equity are classified as liabilities. In such instances, net-cash settlement is assumed for financial reporting purposes, even when the terms of the underlying contracts do not provide for a net-cash settlement. Such financial instruments are initially recorded at fair value with subsequent changes in fair value charged (credited) to operations in each reporting period. If these instruments subsequently meet the requirements for classification as equity, the Company reclassifies the fair value to equity.
	Net income (loss) per common share
	Basic net income (loss) per share of Common Stock has been computed by dividing net income (loss) by the weighted average number of shares outstanding during the period. Diluted net income per share of Common Stock has been computed by dividing net income by the weighted average number of shares outstanding plus the dilutive effect, if any, of outstanding stock options, warrants and convertible securities. Diluted net loss per share of Common Stock has been computed by dividing the net loss for the period by the weighted average number of shares of Common Stock outstanding during such period. In a net loss period, options, warrants and convertible securities are anti-dilutive and therefore excluded from diluted loss per share calculations.
	Recent Accounting Pronouncements
	In July 2013, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2013-11 Income Taxes (Topic 740)—Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists that provides guidance on whether an uncertain tax position should be presented as a reduction to a deferred tax asset or as a separate liability. This guidance seeks to address diversity in practice. This ASU is effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The Company does not expect the adoption of this ASU amendment to have any effect on the financial condition, results of operations or cash flows.

PROPERTY_AND_EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Dec. 31, 2013
PROPERTY AND EQUIPMENT	'
PROPERTY AND EQUIPMENT	'
	3. PROPERTY AND EQUIPMENT
	Property and equipment, net consisted of the following:
		2013			2012
	Computer software and hardware	$	559,934		$	362,352
	Research and lab equipment		1,881,656			1,448,226
	Leasehold improvements		381,225			298,222
	Office Equipment		790,746			756,301
	Less accumulated depreciation and amortization		(1,276,351	)		(553,159	)
	Property and equipment, net	$	2,337,210		$	2,311,942

INTANGIBLE_ASSETS

INTANGIBLE ASSETS	12 Months Ended
	Dec. 31, 2013
INTANGIBLE ASSETS	'
INTANGIBLE ASSETS	'
	4. INTANGIBLE ASSETS
	Intangible assets, included in Other Assets, consist of patent licensing fees paid to license intellectual property (see Note 16. The Company is amortizing the license fee to research and development expense over its 15-year term.
		2013			2012
	Patent licensing fee	$	200,000		$	200,000
	Accumulated amortization		(68,861	)		(51,361	)
		$	131,139		$	148,639
	For the years ended December 31, 2013, 2012, and 2011 the amortization expense was $17,500, $17,500, and $12,500. Amortization expense in each of the next five years is expected to be approximately $17,000 per year.

ACCRUED_EXPENSES

ACCRUED EXPENSES	12 Months Ended
	Dec. 31, 2013
ACCRUED EXPENSES	'
ACCRUED EXPENSES	'
	5. ACCRUED EXPENSES
	Accrued expenses consisted of the following:
		December 31,
		2013		2012
	Accrued bonus	$	565,489	$	—
	Accrued payroll		101,283		224,596
	Deferred rent payable		553,285		310,076
	Accrued vacation		23,188		—
	Other accrued expenses		48,940		486,603
		$	1,292,185	$	1,021,275

NOTE_PAYABLE

NOTE PAYABLE	12 Months Ended
	Dec. 31, 2013
NOTE PAYABLE	'
NOTE PAYABLE	'
	6. NOTE PAYABLE
	In May 2013, the Company entered into a contract for the purchase of an Enterprise Resource Planning ("ERP") system for approximately $150,000. The total cost for the ERP system including interest is approximately $159,000 with an implicit interest rate of approximately 6%.
	Pursuant to the terms of this non-cancelable purchase agreement ("Note payable") in effect at December 31, 2013, the future minimum principal payments are as follows:
	Year Ended December 31,
	2014	$	73,987
	2015		18,497
	Total	$	92,484
	In the third quarter of 2013, the Company decided to abandon the implementation of the ERP system. As such, the purchase was fully expensed in 2013. The Company will reserve the right to implement the ERP system at a future date.

FAIR_VALUES_OF_ASSETS_AND_LIAB

FAIR VALUES OF ASSETS AND LIABILITIES	12 Months Ended
	Dec. 31, 2013
FAIR VALUES OF ASSETS AND LIABILITIES	'
FAIR VALUES OF ASSETS AND LIABILITIES	'
	7. FAIR VALUES OF ASSETS AND LIABILITIES
	The Company groups its assets and liabilities generally measured at fair value in three levels, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value.
	Level 1—Valuation is based on quoted prices in active markets for identical assets or liabilities. Level 1 assets and liabilities generally include debt and equity securities that are traded in an active exchange market. Valuations are obtained from readily available pricing sources for market transactions involving identical assets or liabilities.
	Level 2—Valuation is based on observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level 3—Valuation is based on unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation.
	The Company uses valuation methods and assumptions that consider among other factors the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value for the warrants considered to be derivative instruments.
	Assets and liabilities measured at fair value on a recurring basis are summarized below:
		December 31, 2012
		Level 1		Level 2		Level 3		Fair Value
	Liabilities:
	Derivative warrant liability	$	—	$	14,584,818	$	—	$	14,584,818
	There were no assets or liabilities measured at fair value on a recurring basis at December 31, 2013.

CAPITAL_LEASE_PAYABLE

CAPITAL LEASE PAYABLE	12 Months Ended
	Dec. 31, 2013
CAPITAL LEASE PAYABLE	'
CAPITAL LEASE PAYABLE	'
	8. CAPITAL LEASE PAYABLE
	In February 2011, the Company entered into a capital lease agreement under which the Company leased certain laboratory equipment. Capital lease obligation consisted of the following:
		December 31,
		2013			2012
	Capital lease payable	$	2,799		$	35,405
	Less: current portion		(2,799	)		(32,606	)
		$	—		$	2,799
	The total value of the laboratory equipment acquired under this capital lease agreement was $124,151 including a down payment of approximately $31,000. The capital lease is payable in monthly installments of $2,812 payable over thirty six months with the final payment due in January 2014. For the years ended December 31, 2013 and 2012, interest expense recorded on the capital lease was $1,133 and $3,189, respectively. For the years ended December 31, 2013, 2012, and 2011, depreciation expense on the assets under capital lease was $24,831, $24,831 and $22,761, respectively. The net book value at December 31, 2013 and 2012 amounted to $51,730 and $76,559, respectively.

LOAN_PAYABLE

LOAN PAYABLE	12 Months Ended
	Dec. 31, 2013
LOAN PAYABLE	'
LOAN PAYABLE	'
	9. LOAN PAYABLE
	In October 2012, the Company entered into a loan agreement with the Massachusetts Development Finance Agency ("MassDev") from the Commonwealth of Massachusetts's Emerging Technology fund. The loan agreement provides the Company with a $2,000,000 line of credit, with $200,000 to be used for working capital purposes and the remainder of which is to be used for the purchase of capital equipment. The annual interest rate is fixed at 6.5% with interest payments only commencing on November 1, 2012 for the first thirty months and then equal interest and principal payments over the next fifty-four months with the final maturity on October 5, 2019. Based on the $1,920,000 balance outstanding as of December 31, 2013, equal monthly principal payments of $35,556 will be due commencing on May 1, 2015. Therefore, for the years ending December 31, 2015, 2016, 2017, 2018, and 2019 principal payments of approximately $284,444, $426,667, $426,667, $426,667, and $355,555 respectively, will be due. In September 2012, the Company was assessed commitment fees totaling $15,000, which was charged to interest expense. In October 2012 as part of the commitment fee, the Company issued MassDev a warrant for the purchase of 36,145 shares of Common Stock. The warrant has a seven year term and is exercisable at $1.66 per share. The fair value of the warrant was determined to be $31,916 and was recorded as a deferred financing cost and is being amortized to interest expense over a seven year period commencing in October 2012. Amortization of the deferred financing cost for the year ended December 31, 2013 and 2012 was $4,560 and $1,140 respectively and was included in interest expense. The equipment line of credit is secured by substantially all the assets of the Company excluding intellectual property. During 2013, the Company drew on the line and received proceeds of $342,000, for capital equipment. Interest expense related to this loan was $119,817 for the year ended December 31, 2013 and $14,794 for the year ended December, 31 2012.
	In June 2011, the Company entered into a loan agreement with a bank. The loan agreement had provided the Company with a $1,000,000 line of credit for the purchase of capital equipment. The annual interest rate was the greater of 6.75% or 3.50% above the Prime Rate. Borrowings were repayable in equal monthly installments over a thirty six month period. The Company was assessed commitment fees totaling $10,000 and issued the bank a warrant for the purchase of 16,071 shares of Common Stock. The warrant has a seven year term and is exercisable at $1.40 per share. The fair value of the warrant was determined to be approximately $10,000 and was recorded as a deferred financing cost that was being amortized to interest expense over the life of the loan. Under the terms of the MassDev loan disclosed above, in October 2012 the Company repaid the outstanding balance of $134,372 due to the bank and wrote off the remaining deferred financing costs. Amortization of deferred interest on this loan for the years ended December 31, 2012 and 2011 was $6,219 and $4,146, respectively, and was included in interest expense. Interest expense related to the loan payable to the bank was $16,428 and $8,334 for the years ended December 31, 2012 and 2011, respectively.
	At December 31, loans payable consist of the following:
		December 31,
		2013		2012
	Equipment Loan	$	1,920,000	$	1,578,000
	Less: current portion		—		—
		$	1,920,000	$	1,578,000

INCOME_TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2013
INCOME TAXES	'
INCOME TAXES	'
	10. INCOME TAXES
	No provision or benefit for federal or state income taxes has been recorded, as the Company has incurred a net loss for all of the periods presented, and the Company has provided a full valuation allowance against its deferred tax assets.
	At December 31, 2013, the Company had Federal and Massachusetts net operating loss carryforwards of approximately $41,615,000 and $35,656,000, respectively, of which federal carryforwards will expire in varying amounts beginning in 2026. Massachusetts net operating losses began to expire in 2011. Utilization of net operating losses may be subject to substantial annual limitations due to the "change in ownership" provisions of the Internal Revenue Code, and similar state provisions. The annual limitations may result in the expiration of net operating losses before utilization. The Company also had research and development tax credit carryforwards at December 31, 2013 of approximately $680,000 which will begin to expire in 2021 unless previously utilized.
	Significant components of the Company's net deferred tax asset are as follows:
		December 31,
		2013			2012
	Net operating loss carryforward	$	16,031,911		$	10,329,617
	Research and development credit carryforward		624,902			329,584
	Stock-based compensation		2,411,438			1,090,746
	Depreciation and amortization		(148,802	)		(81,305	)
	Accrued expenses		448,563			—
	Charitable contributions		111,776			72,693
	Subtotal		19,479,788			11,741,335
	Valuation allowance		(19,479,788	)		(11,741,335	)
	Net deferred taxes	$	—		$	—
	The Company has maintained a full valuation allowance against its deferred tax assets in all periods presented. A valuation allowance is required to be recorded when it is more likely than not that some portion or all of the net deferred tax assets will not be realized. Since the Company cannot be assured of generating taxable income and thereby realizing the net deferred tax assets, a full valuation allowance has been provided. In the years ended December 31, 2013 and 2012, the valuation allowance increased by $7,738,000 and $4,778,000, respectively.
	The Company has no uncertain tax positions at December 31, 2013 and 2012 that would affect its effective tax rate. The Company does not anticipate a significant change in the amount of uncertain tax positions over the next twelve months. Since the Company is in a loss carryforward position, the Company is generally subject to US federal and state income tax examinations by tax authorities for all years for which a loss carryforward is available.
	Income tax benefits computed using the federal statutory income tax rate differs from the Company's effective tax rate primarily due to the following:
		December 31,
		2013			2012			2011
	Statutory rate		(34.0	)%		34	%		(34.0	)%
	State taxes, net of benefit		(2.6	)%		(14.2	)%		(1.4	)%
	Permanent differences:
	Derivative losses		17.1	%		(127.4	)%		25.7	%
	Other		0	%		(1.9	)%		0.2	%
	R&D tax credit		(0.4	)%		7	%		(0.2	)%
	Increase in valuation reserve		19.9	%		102.5	%		9.7	%
	Effective tax rate		0	%		0	%		0	%

COMMON_STOCK

COMMON STOCK	12 Months Ended
	Dec. 31, 2013
COMMON STOCK	'
COMMON STOCK	'
	11. COMMON STOCK
	The Company has authorized 200,000,000 shares of Common Stock, $0.00001 par value per share, of which 78,773,736, shares were issued and outstanding as of December 31, 2013, and 65,881,122 shares were issued and outstanding as of December 31, 2012.
	During the year ended December 31, 2013, the Company issued 588,884 shares of Common Stock upon the exercise of stock options and received cash proceeds of approximately $455,550.
	During the year ended December 31, 2013, the Company issued 12,224,846 shares of Common Stock upon the exercise of warrants, including warrants to purchase 627,036 shares of Common Stock exercised through cashless exercise provisions and warrants to purchase 11,813,334 shares of Common Stock exercised for cash, providing cash proceeds of approximately $15,952,000.
	During the year ended December 31, 2013, the Company issued 78,884 shares of Common Stock with a fair value of $191,802 to the Company's 401(k) plan as a matching contribution.
	In February 2012, the Company completed a public offering of Common Stock and issued 9,523,810 shares of Common Stock at a purchase price of $2.10 per common share. The offering raised gross proceeds of approximately $20,000,000 and the Company received net proceeds of $18,155,000 after deducting underwriter discounts and offering expenses.
	During 2012, the Company issued 15,000 unregistered shares of Common Stock with a fair value of approximately $25,000 to an investor relations firm in exchange for services provided.
	During the year ended December 31, 2012, the Company issued 755,020 shares of Common Stock upon the exercise of stock options and received cash proceeds of approximately $112,000.
	During the year ended December 31, 2012, the Company issued 1,779,716 shares of Common Stock upon the exercise of warrants, including warrants to purchase 1,865,670 shares of Common Stock exercised through cashless exercise provisions and warrants to purchase 852,946 shares of Common Stock exercised for cash, providing cash proceeds of $1,129,000.
	In December 2011, the Company completed a private placement with an investor that raised $2,000,000 of net proceeds. In this transaction the Company issued 980,392 shares of unregistered common stock and a warrant to purchase 343,137 shares exercisable at $03.06 per share with a five year term. The warrant was recorded as a debit and credit to additional paid-in capital.
	During 2011, the Company issued 143,731 shares of Common Stock upon the exercise of stock options and received cash proceeds of approximately $10,000.
	During 2011, the Company issued 215,000 unregistered shares with a fair value of approximately $198,000 to an investor relations firms in exchange for services provided.
	In 2011, the Company issued 39,848 shares with a fair value of approximately $42,000 to the Company's 401(k) plan as a matching contribution.
	During the fourth quarter of 2011, the Company issued 734,329 shares upon the exercise of warrants and received cash proceeds of approximately $988,000.
	Common Stock Reserves
	As of December 31, 2013, the Company had the following reserves established for the future issuance of Common Stock as follows:
	Reserves for the exercise of warrants	3,283,134
	Reserves for the exercise of stock options	12,979,197
	Total Reserves	16,262,331

DERIVATIVE_INSTRUMENTS

DERIVATIVE INSTRUMENTS	12 Months Ended
	Dec. 31, 2013
DERIVATIVE INSTRUMENTS	'
DERIVATIVE INSTRUMENTS	'
	12. DERIVATIVE INSTRUMENTS
	Certain warrants issued to investors and the placement agent warrants in the fourth quarter of 2010 had provisions that included anti-dilution protection and, under certain conditions, granted the right to the holder to require the Company to repurchase the warrant. Accordingly through March 2013, these warrants were accounted for as derivative liabilities. In the quarter ended March 31, 2013, $476,426 was reclassified from Derivative warrant liability to Additional paid-in capital related to warrants exercised. In May 2013, the Company called for the redemption of all the outstanding investor warrants and during the quarter ended June 30, 2013, all such warrants, for a total of 11,726,343 warrants, were exercised and the fair value of $25,241,401 was reclassified from Derivative warrant liability to Additional paid-in capital. There were no derivative instruments subsequent to June 30, 2013.
	On May 17, 2013, the Company completed its offer to exchange certain of its outstanding warrants to purchase shares of the Company's common stock (the "Eligible Warrants") for new warrants (the "New Warrants") with the same terms except (i) the expiration date of the New Warrants was extended two years and (ii) weighted average anti-dilution provisions were removed from the New Warrants (the "Offer"). The Eligible Warrants consisted of (i) warrants to purchase common stock dated October 26, 2010, issued in connection with the closing of a merger (the "Merger Warrants") and (ii) warrants to purchase common stock issued to the placement agent as compensation for services in connection with each closing of a private placement which occurred on October 26, 2010, November 10, 2010 and December 3, 2010 (the "Placement Agent Warrants"). In connection with the Offer, Merger Warrants to purchase 255,000 shares of the Company's common stock and Placement Agent Warrants to purchase 3,064,091 shares of the Company's common stock were tendered and accepted for exchange for New Warrants to purchase an aggregate of 3,319,091 shares of the Company's common stock. Due to the modification of the terms, the Eligible Warrants were revalued prior to modification and immediately after modification as of May 17, 2013. This resulted in an incremental fair value immediately after the modification and the Derivative warrant liability was increased by $764,769 and a corresponding non-cash charge was recorded in Other expense as Loss from modification of warrants. Since the New Warrants are not accounted for as derivative liabilities, the fair value of these warrants after modification of $7,738,320 was reclassified from Derivative warrant liability to Additional paid-in capital.
	The Company used the Black-Scholes option pricing model and assumptions that consider among other factors the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value for the warrants considered to be derivative instruments. The fair value of these derivative instruments at December 31, 2013 and 2012 was $0 and $14,584,818, respectively and was included as a derivative warrant liability, a current liability. Changes in fair value of the derivative financial instruments are recognized currently in the Statement of Operations as a derivatives gain or loss. The warrant derivative gains (losses) are non-cash income (expenses) and for the years ended December 31, 2013, 2012, and 2011 were $(18,871,329), $17,479,674, and $(26,065,579), respectively, were included in other income (expense) in the consolidated statements of operations.
	The assumptions used principally in determining the fair value of warrants were as follows:
		2012		2011
	Risk free interest rate	0.32 - 0.35%		0.52 - 0.58%
	Expected dividend yield	0%		0%
	Contractual term	2.7 - 2.9 years		3.7 - 3.9 years
	Expected volatility	73%		79%
	The primary underlying risk exposure pertaining to the warrants is the change in fair value of the underlying Common Stock for each reporting period.
	The table below presents the changes in derivative warrant liability during the years ended December 31, 2013, 2012, and 2011:
		Year Ended December 31,
		2013			2012			2011
	Balance at beginning of year	$	14,584,818		$	35,473,230		$	10,647,190
	Increase (decrease) in the fair value of the warrants		18,871,329			(17,479,674	)		26,065,579
	Reduction in derivative liability due to exercise of warrants		(33,456,147	)		(3,408,738	)		(1,239,539	)
	Balance at end of year	$	—		$	14,584,818		$	35,473,230

STOCK_OPTIONS

STOCK OPTIONS	12 Months Ended
	Dec. 31, 2013
STOCK OPTIONS	'
STOCK OPTIONS	'
	13. STOCK OPTIONS
	In 2007, the Company adopted the 2007 Employee, Director and Consultant Stock Plan (the "2007 Plan"). Pursuant to the 2007 Plan, the Company's Board of Directors (or committees and/or executive officers delegated by the Board of Directors) may grant incentive and nonqualified stock options to the Company's employees, officers, directors, consultants and advisors. As of December 31, 2013, there were options to purchase an aggregate of 2,198,050 shares of Common Stock outstanding under the 2007 Plan and no shares available for future grants under the 2007 Plan.
	On October 26, 2010, the Company's Board of Directors adopted and the Company's shareholders subsequently approved the 2010 Equity Incentive Plan, (the "2010 Plan"). The 2010 Plan provides for grants of incentive stock options to employees and nonqualified stock options and restricted Common Stock to employees, consultants and non-employee directors of the Company. As of December 31, 2013, the number of shares authorized for issuance under the 2010 Plan, as amended, was 11,000,000 shares. As of December 31, 2013, there were options to purchase an aggregate of 5,857,472 shares of Common Stock outstanding under the 2010 Plan and 4,923,675 shares available for future grants under the 2010 Plan. Options issued under the 2007 Plan and the 2010 Plan (collectively the "Plans") are exercisable for up to 10 years from the date of issuance.
	Share-based compensation
	For stock options issued and outstanding for the years ended December 31, 2013, 2012 and 2011, the Company recorded non-cash, stock-based compensation expense of $3,135,646, $1,232,959 and $921,512, respectively, net of forfeitures.
	The fair value of each option award is estimated on the date of grant using the Black-Scholes option pricing model that uses the assumptions noted in the following table. Due to its limited operating history and limited number of sales of its Common Stock, the Company estimated its volatility in consideration of a number of factors including the volatility of comparable public companies. The Company uses historical data, as well as subsequent events occurring prior to the issuance of the financial statements, to estimate option exercises and employee terminations within the valuation model. The expected term of options granted under the Plans, all of which qualify as "plain vanilla," is based on the average of the contractual term (10 years) and the vesting period (generally 48 months). For non-employee options, the expected term is the contractual term. The risk-free rate is based on the yield of a U.S. Treasury security with a term consistent with the option.
	The assumptions used principally in determining the fair value of options granted were as follows:
		December 31,
		2013		2012		2011
	Risk-free interest rate	0.77 - 2.52%		0.62 - 1.23%		0.97 - 3.05%
	Expected dividend yield	0%		0%		0%
	Expected term (employee grants)	6.25		6.25		6.25
	Expected volatility	102%		75%		49%
	A summary of option activity as of December 31, 2013 and changes for the year then ended are presented below:
	Options	Shares			Weighted		Weighted		Aggregate
					Average		Average		Intrinsic
					Exercise		Remaining		Value
					Price		Contractual
							Term in
							Years
	Outstanding at December 31, 2012		8,648,268		$	1.29
	Granted		3,035,000		$	2.23
	Forfeited		(2,902,584	)	$	1.63
	Exercised		(725,162	)	$	0.88
	Outstanding at December 31, 2013		8,055,522		$	1.56		7.55	$	6,704,149
	Vested at December 31, 2013		3,661,215		$	0.91		5.5	$	5,035,700
	The weighted average grant-date fair value of options granted during years ended December 31, 2013, 2012, and 2011 was $2.04, $1.28, and $1.14 per share, respectively. The total fair value of options that vested in years ended December 31, 2013, 2012, and 2011 was $1,985,034, $1,186,098 and $1,324,325 respectively. As of December 31, 2013, there was approximately $6,277,267 of total unrecognized compensation expense, related to non-vested share-based option compensation arrangements. The unrecognized compensation expense is estimated to be recognized over a period of 3.09 years at December 31, 2013.
	In September 2011, the Company granted 80,000 shares of Common Stock under the 2010 Plan to a consultant as a restricted stock award with 30,000 shares vesting upon FDA clearance of an Investigational Device Exemption to permit the commencement of a human clinical trial and 50,000 shares vesting upon FDA approval of the Company's biopolymer scaffolding device to treat spinal cord injuries. The Company had previously determined that the vesting of the 30,000 shares was probable and the fair value of these shares at $23,400 was being amortized over an eight month period from September 2011 through April 2012. In March of 2012, the contract with the consultant was terminated and the consultant had no vested right to the restricted stock, so accordingly, the $11,700 of expense previously recorded was reversed in 2012.

WARRANTS

WARRANTS	12 Months Ended
	Dec. 31, 2013
WARRANTS	'
WARRANTS	'
	14. WARRANTS
	The following presents information about warrants to purchase Common Stock issued and outstanding at December 31, 2013:
	Year Issued	Classification	Number of		Exercise		Date of Expiration
			Warrants		Price
	2010	Equity		1,533,163	$	1.4	10/26/2017 - 12/3/2017
	2010	Equity		1,354,618	$	1	9/26/2015 - 12/3/2015
	2011	Equity		16,071	$	1.4	6/17/18
	2011	Equity		343,137	$	3.06	12/21/16
	2012	Equity		36,145	$	1.66	10/5/19
	Total			3,283,134
	Weighted average exercise price				$	1.41
	Weighted average life in years						3.62

EMPLOYEE_BENEFIT_PLAN

EMPLOYEE BENEFIT PLAN	12 Months Ended
	Dec. 31, 2013
EMPLOYEE BENEFIT PLAN	'
EMPLOYEE BENEFIT PLAN	'
	15. EMPLOYEE BENEFIT PLAN
	In November 2006, the Company adopted a 401(k) plan (the "Plan") covering all employees. Employees must be 21 years of age in order to participate in the Plan. Under the Plan, the Company has the option to make matching contributions. For the years ended December 31, 2013, 2012 and 2011, the Company made matching contributions in the form of shares of common stock. For the years ended December 31, 2013, 2012, and 2011, the Company issued 78,884, 47,105, and 39,848 shares of common stock, respectively, and related fair values of $191,802, $91,524, and $41,662, respectively, were recorded as expense in the Statement of Operations.

INTELLECTUAL_PROPERTY_LICENSE

INTELLECTUAL PROPERTY LICENSE	12 Months Ended
	Dec. 31, 2013
INTELLECTUAL PROPERTY LICENSE	'
INTELLECTUAL PROPERTY LICENSE	'
	16. INTELLECTUAL PROPERTY LICENSE
	The Company has a world-wide exclusive license (the "CMCC License") for patents co-owned by Massachusetts Institute of Technology and Harvard's Children's Hospital initially covering the use of biopolymers to treat spinal cord injuries, and to promote the survival and proliferation of human stem cells in the spinal cord. During 2011, the Company obtained additional rights for use in the field of peripheral nerve injuries. The CMCC License has a 15-year term, or as long as the life of the last expiring patent right, whichever is longer, unless terminated earlier by the licensor. In connection with the CMCC License, the Company paid an initial $75,000 licensing fee and is required to pay certain annual maintenance fees, milestone payments and royalties. During 2011, the Company paid $75,000 to expand the license and at December 31, 2011, accrued $50,000 for a milestone payment. License fees are capitalized and all costs associated with maintenance of the CMCC License are expensed as incurred (see Note 4).

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2013
COMMITMENTS AND CONTINGENCIES	'
COMMITMENTS AND CONTINGENCIES	'
	17. COMMITMENTS AND CONTINGENCIES
	On November 30, 2011 and as amended on September 17, 2012, the Company entered into a commercial lease for 26,150 square feet of office, laboratory and manufacturing space in Cambridge, Massachusetts ("Cambridge Lease"). The term of this lease is six years and three months, with one five-year extension option. The terms of the lease requires a standby letter of credit, as amended, in the amount of $311,365 (see Note 2).
	The Cambridge Lease contains rent holidays and rent escalation clauses. The Company recognizes rent expense on a straight-line basis over the lease term and record the difference between the amount charged to expense and the rent paid as a deferred rent liability. As of December 31, 2013, the amount of deferred rent liability is $553,285 and is included in Accrued expenses.
	It is the Company's policy to assess whether improvements made to the space rented under operating leases should be accounted for as lessor or lessee assets. If the landlord/lessor makes the improvements and presents us with the finished space on a "turnkey" basis, we view the assets as being lessor assets. When the Company does the remodeling work and receives an allowance that may or may not cover all the costs, the Company makes a judgment as to the classification between lessor and lessee assets. The Company considers an asset to be a lessor asset if all of the following criteria are met:
	•
	the lease specifically requires the lessee to make the improvement,
	•
	the improvement is fairly generic,
	•
	the improvement increases the fair value of the property to the lessor, and
	•
	the useful life of the improvement is longer than our lease term.
	If any of the above criteria are not met, the Company considers the assets to be lessee assets, which are recorded as leasehold improvements in the balance sheet and payments received from the lessor to fund any portion of the cost of lessee assets are accounted for as lease incentives. Assets considered to be lessor assets are not reflected in the Company's Consolidated Balance Sheets. To the extent that the Company paid for such lessor assets and was not reimbursed through construction allowances, such net payments are recorded as leasehold improvements, which are amortized to rent expense over the lease term. As of December 31, 2013, such leasehold improvements totaled $381,225.
	Pursuant to the terms of the non-cancelable lease agreements in effect at December 31, 2013, the future minimum rent commitments are as follows:
	Year Ended December 31,
	2014		1,202,585
	2015		1,242,559
	2016		1,268,708
	2017		1,294,860
	2018		1,049,420
	Total	$	6,058,132
	Total rent expense for the years ended December 31, 2013, 2012, and 2011, including month-to-month leases, was $1,125,000, $758,000, and $357,000, respectively.
	On September 4, 2013, the Company entered into a legal settlement agreement for approximately $286,000, in connection with the settlement of outstanding litigation, which has been included in the deferred rent liability and the benefit will be amortized over the remainder of the lease term.
	Litigation
	The Company has certain claims and pending legal proceedings in the ordinary course of business. In the opinion of management, such proceedings are not expected to have a material adverse effect on the Company's financial position, results of operations and cash flows.
	In November 2013, we filed a lawsuit against Francis Reynolds, the Company's former Chairman, Chief Executive Officer and Chief Financial Officer, in Middlesex Superior Court, Middlesex County, Massachusetts (InVivo Therapeutics Holdings Corp. v. Reynolds, Civil Action No. 13-5004). The complaint alleges breaches of fiduciary duties, breach of contract, conversion, misappropriation of corporate assets, unjust enrichment, corporate waste, and seeks money damages and an accounting. The lawsuit involves approximately $500,000 worth of personal and/or exorbitant expenses that the Company alleges Mr. Reynolds inappropriately caused the Company to pay while he was serving as the Company's Chief Executive Officer, Chief Financial Officer, President and Chairman of the Board of Directors. On December 6, 2013, Mr. Reynolds answered the complaint, and filed counterclaims against the Company and its Board of Directors. The counterclaims allege two counts of breach of contract, two counts of breach of the covenant of good faith and fair-dealing, and tortious interference with a contract, and seek monetary damages and a declaratory judgment. The counterclaims involve Mr. Reynolds's allegations that the Company and the Board interfered with the performance of his duties under the terms of his employment agreement, and that Mr. Reynolds was entitled to additional shares upon the exercise of certain stock options. On January 9, 2014, the Company and directors named in the counterclaims filed their answer. We expect discovery to begin soon. No judgments or rulings are pending at this early stage. We do not believe that the pending actions will materially impact the financial condition of the Company.

INSURANCE_CLAIM

INSURANCE CLAIM	12 Months Ended
	Dec. 31, 2013
INSURANCE CLAIM	'
INSURANCE CLAIM	'
	18. INSURANCE CLAIM
	During the year ended December 31, 2013, the Company received insurance proceeds of approximately $1,100,000 from the settlement of a business interruption claim that covered the disruption of the Company's operations at its facility in Cambridge, MA caused by water damage that occurred in November 2012. The insurance settlement reimbursed the Company for costs incurred as a result of the disruption is included as reduction of Research and Development Expense in the Consolidated Statement of Operations for the year ended December 31, 2013.

SIGNIFICANT_ACCOUNTING_POLICIE1

SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2013
SIGNIFICANT ACCOUNTING POLICIES	'
Use of estimates	'
	Use of estimates
	The process of preparing financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and changes in estimates may occur.
Principles of consolidation	'
	Principles of consolidation
	The consolidated financial statements include the accounts of InVivo Therapeutics Holdings Corp. and its wholly-owned subsidiary, InVivo Therapeutics Corporation. All significant intercompany balances and transactions have been eliminated in consolidation.
Cash and cash equivalents	'
	Cash and cash equivalents
	The Company considers only those investments which are highly liquid, readily convertible to cash, and that mature within three months from date of purchase to be cash equivalents. Marketable investments are those with original maturities in excess of three months.
	At December 31, 2013 and 2012, cash equivalents were comprised of money market funds. The Company had no marketable investments at December 31, 2013 and 2012.
	Cash and cash equivalents consist of the following:
		December 31,
		2013		2012
	Cash on deposit	$	219,378	$	209,380
	Money market fund		13,760,943		12,615,710
	Total cash and cash equivalents	$	13,980,321	$	12,825,090
Restricted cash	'
	Restricted cash
	Restricted cash of $601,471 represents a $290,106 security deposit related to the Company's credit card account, and a $311,365 standby letter of credit in favor of a landlord (see Note 17).
Financial instruments	'
	Financial instruments
	The carrying amounts reported in the consolidated balance sheet for cash and cash equivalents and accounts payable approximate fair value based on the short-term nature of these instruments. The carrying value of note and loans payable approximates their fair value due to the market terms.
Property and equipment	'
	Property and equipment
	Property and equipment are carried at cost. Depreciation expense is provided over the estimated useful lives of the assets using the straight-line method. A summary of the estimated useful lives is as follows:
	Classification	Estimated Useful Life
	Computer hardware	5 years
	Software	3 years
	Office furniture and equipment	5 years
	Research and lab equipment	5 years
	Leasehold improvements	Remaining Life of Lease
	Depreciation expense for the years ended December 31, 2013, 2012, and 2011 was $723,192, $349,393, and $132,162 respectively. Maintenance and repairs are charged to expense as incurred, while any additions or improvements are capitalized.
Research and development expenses	'
	Research and development expenses
	Costs incurred for research and development are expensed as incurred.
Concentrations of credit risk	'
	Concentrations of credit risk
	The Company has no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other hedging arrangements. The Company may from time to time have cash in banks in excess of FDIC insurance limits.
Segment information	'
	Segment information
	Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision making group, in making decisions regarding resource allocation and assessing performance. To date, the Company has viewed its operations and manages its business as principally one operating segment, which is developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. As of December 31, 2013 and 2012, all of the Company's assets were located in the United States.
Income taxes	'
	Income taxes
	For federal and state income taxes, deferred tax assets and liabilities are recognized based upon temporary differences between the financial statement and the tax basis of assets and liabilities. Deferred income taxes are based upon prescribed rates and enacted laws applicable to periods in which differences are expected to reverse. A valuation allowance is recorded when it is more likely than not that some portion or all of the deferred tax assets will not be realized. Accordingly, the Company provides a valuation allowance, if necessary, to reduce deferred tax assets to amounts that are realizable. Tax positions taken or expected to be taken in the course of preparing the Company's tax returns are required to be evaluated to determine whether the tax positions are "more-likely-than-not" of being sustained by the applicable tax authority.
	Tax positions not deemed to meet a more-likely-than-not threshold would be recorded as a tax expense in the current year. There were no uncertain tax positions that require accrual or disclosure to the financial statements as of December 31, 2013 or 2012. Tax years subsequent to 2009 remain open to examination by U.S. federal and state tax authorities.
Impairment of long-lived assets	'
	Impairment of long-lived assets
	The Company continually monitors events and changes in circumstances that could indicate that carrying amounts of long-lived assets may not be recoverable. An impairment loss is recognized when expected cash flows are less than an asset's carrying value. Accordingly, when indicators of impairment are present, the Company evaluates the carrying value of such assets in relation to the operating performance and future undiscounted cash flows of the underlying assets. The Company's policy is to record an impairment loss when it is determined that the carrying value of the asset may not be recoverable. No impairment charges were recorded for the years ended December 31, 2013, 2012 and 2011.
Share-based payments	'
	Share-based payments
	The Company recognizes compensation costs resulting from the issuance of stock-based awards to employees, non-employees and directors as an expense in the statement of operations over the service period based on a measurement of fair value for each stock-based award. The fair value of each option grant is estimated as of the date of grant using the Black-Scholes option-pricing model. The fair value is amortized as compensation cost on a straight-line basis over the requisite service period of the awards, which is generally the vesting period. Due to its limited operating history, limited number of sales of its Common Stock and limited history of its shares being publicly traded, the Company estimates its volatility in consideration of a number of factors including the volatility of comparable public companies.
Derivative instruments	'
	Derivative instruments
	The Company generally does not use derivative instruments to hedge exposures to cash-flow or market risks; however, certain warrants to purchase Common Stock that do not meet the requirements for classification as equity are classified as liabilities. In such instances, net-cash settlement is assumed for financial reporting purposes, even when the terms of the underlying contracts do not provide for a net-cash settlement. Such financial instruments are initially recorded at fair value with subsequent changes in fair value charged (credited) to operations in each reporting period. If these instruments subsequently meet the requirements for classification as equity, the Company reclassifies the fair value to equity.
Net income (loss) per common share	'
	Net income (loss) per common share
	Basic net income (loss) per share of Common Stock has been computed by dividing net income (loss) by the weighted average number of shares outstanding during the period. Diluted net income per share of Common Stock has been computed by dividing net income by the weighted average number of shares outstanding plus the dilutive effect, if any, of outstanding stock options, warrants and convertible securities. Diluted net loss per share of Common Stock has been computed by dividing the net loss for the period by the weighted average number of shares of Common Stock outstanding during such period. In a net loss period, options, warrants and convertible securities are anti-dilutive and therefore excluded from diluted loss per share calculations.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	In July 2013, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2013-11 Income Taxes (Topic 740)—Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists that provides guidance on whether an uncertain tax position should be presented as a reduction to a deferred tax asset or as a separate liability. This guidance seeks to address diversity in practice. This ASU is effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The Company does not expect the adoption of this ASU amendment to have any effect on the financial condition, results of operations or cash flows.

SIGNIFICANT_ACCOUNTING_POLICIE2

SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2013
SIGNIFICANT ACCOUNTING POLICIES	'
Schedule of cash and cash equivalents	'
		December 31,
		2013		2012
	Cash on deposit	$	219,378	$	209,380
	Money market fund		13,760,943		12,615,710
	Total cash and cash equivalents	$	13,980,321	$	12,825,090
Summary of estimated useful lives	'
	Classification	Estimated Useful Life
	Computer hardware	5 years
	Software	3 years
	Office furniture and equipment	5 years
	Research and lab equipment	5 years
	Leasehold improvements	Remaining Life of Lease

PROPERTY_AND_EQUIPMENT_Tables

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2013
PROPERTY AND EQUIPMENT	'
Schedule of property and equipment, net	'
		2013			2012
	Computer software and hardware	$	559,934		$	362,352
	Research and lab equipment		1,881,656			1,448,226
	Leasehold improvements		381,225			298,222
	Office Equipment		790,746			756,301
	Less accumulated depreciation and amortization		(1,276,351	)		(553,159	)
	Property and equipment, net	$	2,337,210		$	2,311,942

INTANGIBLE_ASSETS_Tables

INTANGIBLE ASSETS (Tables)	12 Months Ended
	Dec. 31, 2013
INTANGIBLE ASSETS	'
Summary of intangible assets	'
		2013			2012
	Patent licensing fee	$	200,000		$	200,000
	Accumulated amortization		(68,861	)		(51,361	)
		$	131,139		$	148,639

ACCRUED_EXPENSES_Tables

ACCRUED EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2013
ACCRUED EXPENSES	'
Summary of accrued expenses	'
		December 31,
		2013		2012
	Accrued bonus	$	565,489	$	—
	Accrued payroll		101,283		224,596
	Deferred rent payable		553,285		310,076
	Accrued vacation		23,188		—
	Other accrued expenses		48,940		486,603
		$	1,292,185	$	1,021,275

NOTE_PAYABLE_Tables

NOTE PAYABLE (Tables)	12 Months Ended
	Dec. 31, 2013
NOTE PAYABLE	'
Schedule of future minimum principal payments	'
	Year Ended December 31,
	2014	$	73,987
	2015		18,497
	Total	$	92,484

FAIR_VALUES_OF_ASSETS_AND_LIAB1

FAIR VALUES OF ASSETS AND LIABILITIES (Tables)	12 Months Ended
	Dec. 31, 2013
FAIR VALUES OF ASSETS AND LIABILITIES	'
Summary of assets and liabilities measured at fair value on a recurring basis	'
		December 31, 2012
		Level 1		Level 2		Level 3		Fair Value
	Liabilities:
	Derivative warrant liability	$	—	$	14,584,818	$	—	$	14,584,818

CAPITAL_LEASE_PAYABLE_Tables

CAPITAL LEASE PAYABLE (Tables)	12 Months Ended
	Dec. 31, 2013
CAPITAL LEASE PAYABLE	'
Schedule of capital lease obligation	'
		December 31,
		2013			2012
	Capital lease payable	$	2,799		$	35,405
	Less: current portion		(2,799	)		(32,606	)
		$	—		$	2,799

LOAN_PAYABLE_Tables

LOAN PAYABLE (Tables)	12 Months Ended
	Dec. 31, 2013
LOAN PAYABLE	'
Summary of loan payable	'
		December 31,
		2013		2012
	Equipment Loan	$	1,920,000	$	1,578,000
	Less: current portion		—		—
		$	1,920,000	$	1,578,000

INCOME_TAXES_Tables

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2013
INCOME TAXES	'
Schedule of significant components of net deferred tax asset	'
		December 31,
		2013			2012
	Net operating loss carryforward	$	16,031,911		$	10,329,617
	Research and development credit carryforward		624,902			329,584
	Stock-based compensation		2,411,438			1,090,746
	Depreciation and amortization		(148,802	)		(81,305	)
	Accrued expenses		448,563			—
	Charitable contributions		111,776			72,693
	Subtotal		19,479,788			11,741,335
	Valuation allowance		(19,479,788	)		(11,741,335	)
	Net deferred taxes	$	—		$	—
Schedule of income tax benefits computed using the federal statutory income tax rate differs from effective tax rate	'
		December 31,
		2013			2012			2011
	Statutory rate		(34.0	)%		34	%		(34.0	)%
	State taxes, net of benefit		(2.6	)%		(14.2	)%		(1.4	)%
	Permanent differences:
	Derivative losses		17.1	%		(127.4	)%		25.7	%
	Other		0	%		(1.9	)%		0.2	%
	R&D tax credit		(0.4	)%		7	%		(0.2	)%
	Increase in valuation reserve		19.9	%		102.5	%		9.7	%
	Effective tax rate		0	%		0	%		0	%

COMMON_STOCK_Tables

COMMON STOCK (Tables)	12 Months Ended
	Dec. 31, 2013
COMMON STOCK	'
Schedule of reserves established for future issuance of Common Stock	'
	Reserves for the exercise of warrants	3,283,134
	Reserves for the exercise of stock options	12,979,197
	Total Reserves	16,262,331

DERIVATIVE_INSTRUMENTS_Tables

DERIVATIVE INSTRUMENTS (Tables)	12 Months Ended
	Dec. 31, 2013
DERIVATIVE INSTRUMENTS	'
Fair value of warrants	'
		2012		2011
	Risk free interest rate	0.32 - 0.35%		0.52 - 0.58%
	Expected dividend yield	0%		0%
	Contractual term	2.7 - 2.9 years		3.7 - 3.9 years
	Expected volatility	73%		79%
Changes in derivative warrant liability	'
		Year Ended December 31,
		2013			2012			2011
	Balance at beginning of year	$	14,584,818		$	35,473,230		$	10,647,190
	Increase (decrease) in the fair value of the warrants		18,871,329			(17,479,674	)		26,065,579
	Reduction in derivative liability due to exercise of warrants		(33,456,147	)		(3,408,738	)		(1,239,539	)
	Balance at end of year	$	—		$	14,584,818		$	35,473,230

STOCK_OPTIONS_Tables

STOCK OPTIONS (Tables)	12 Months Ended
	Dec. 31, 2013
STOCK OPTIONS	'
Schedule of assumptions used principally in determining the fair value of options granted	'
		December 31,
		2013		2012		2011
	Risk-free interest rate	0.77 - 2.52%		0.62 - 1.23%		0.97 - 3.05%
	Expected dividend yield	0%		0%		0%
	Expected term (employee grants)	6.25		6.25		6.25
	Expected volatility	102%		75%		49%
Summary of option activity	'
	Options	Shares			Weighted		Weighted		Aggregate
					Average		Average		Intrinsic
					Exercise		Remaining		Value
					Price		Contractual
							Term in
							Years
	Outstanding at December 31, 2012		8,648,268		$	1.29
	Granted		3,035,000		$	2.23
	Forfeited		(2,902,584	)	$	1.63
	Exercised		(725,162	)	$	0.88
	Outstanding at December 31, 2013		8,055,522		$	1.56		7.55	$	6,704,149
	Vested at December 31, 2013		3,661,215		$	0.91		5.5	$	5,035,700

WARRANTS_Tables

WARRANTS (Tables)	12 Months Ended
	Dec. 31, 2013
WARRANTS	'
Schedule of information about warrants to purchase common stock issued and outstanding	'
	Year Issued	Classification	Number of		Exercise		Date of Expiration
			Warrants		Price
	2010	Equity		1,533,163	$	1.4	10/26/2017 - 12/3/2017
	2010	Equity		1,354,618	$	1	9/26/2015 - 12/3/2015
	2011	Equity		16,071	$	1.4	6/17/18
	2011	Equity		343,137	$	3.06	12/21/16
	2012	Equity		36,145	$	1.66	10/5/19
	Total			3,283,134
	Weighted average exercise price				$	1.41
	Weighted average life in years						3.62

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2013
COMMITMENTS AND CONTINGENCIES	'
Future minimum rent commitments	'
	Year Ended December 31,
	2014		1,202,585
	2015		1,242,559
	2016		1,268,708
	2017		1,294,860
	2018		1,049,420
	Total	$	6,058,132

NATURE_OF_OPERATIONS_AND_GOING1

NATURE OF OPERATIONS AND GOING CONCERN (Details) (USD $)

1 Months Ended

12 Months Ended

25 Months Ended

97 Months Ended

1 Months Ended

1 Months Ended

Oct. 31, 2010

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2009

Dec. 31, 2008

Dec. 31, 2007

Dec. 31, 2013

Oct. 31, 2010

Oct. 26, 2010

Oct. 31, 2010

ITHC

ITHC

InVivo

Going concern disclosures

'

'

'

'

'

'

'

'

'

'

'

'

Accumulated loss

'

$81,909,303

$43,153,381

'

'

'

'

'

$81,909,303

'

'

'

Net loss

'

-38,755,922

4,663,681

-34,728,215

-7,910,950

-2,515,878

-1,564,069

-1,097,702

-81,909,055

'

'

'

Cash used in operations

'

-14,905,844

-10,203,779

-7,429,965

'

'

'

'

-39,327,896

'

'

'

Cash balance

'

13,980,321

12,825,090

4,363,712

8,964,194

'

'

'

13,980,321

'

'

'

Reverse Merger

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares issued in relation to business acquisition

'

'

'

'

'

'

'

'

'

31,147,190

'

2,261,862

Stockholder's equity note stock split conversion ratio

'

'

'

'

'

'

'

'

'

'

'

13.7706

Common stock, outstanding

'

78,773,736

65,881,122

'

'

'

'

'

78,773,736

'

6,999,981

'

Net assets

'

'

'

'

'

'

'

'

'

'

$0

'

Shares issued in relation to legal services

500,000

'

'

'

'

'

'

'

'

'

'

'

SIGNIFICANT_ACCOUNTING_POLICIE3

SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Cash and cash equivalents	'	'	'	'
Cash and cash equivalents	$13,980,321	$12,825,090	$4,363,712	$8,964,194
Investments	'	'	'	'
Marketable investments, amount	0	0	'	'
Cash on deposit	'	'	'	'
Cash and cash equivalents	'	'	'	'
Cash and cash equivalents	219,378	209,380	'	'
Money market fund	'	'	'	'
Cash and cash equivalents	'	'	'	'
Cash and cash equivalents	$13,760,943	$12,615,710	'	'

SIGNIFICANT_ACCOUNTING_POLICIE4

SIGNIFICANT ACCOUNTING POLICIES (Details 2) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Restricted cash	'	'
Restricted cash	$601,471	$601,351
Security deposit related to credit card account	'	'
Restricted cash	'	'
Restricted cash	290,106	'
Standby letter of credit in favor of a landlord	'	'
Restricted cash	'	'
Restricted cash	$311,365	'

SIGNIFICANT_ACCOUNTING_POLICIE5

SIGNIFICANT ACCOUNTING POLICIES (Details 3) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Depreciation	'	'	'
Depreciation expense	$723,192	$349,393	$132,162
Computer hardware	'	'	'
Property and equipment	'	'	'
Estimated Useful Life	'5 years	'	'
Software	'	'	'
Property and equipment	'	'	'
Estimated Useful Life	'3 years	'	'
Office Equipment	'	'	'
Property and equipment	'	'	'
Estimated Useful Life	'5 years	'	'
Research and lab equipment	'	'	'
Property and equipment	'	'	'
Estimated Useful Life	'5 years	'	'

SIGNIFICANT_ACCOUNTING_POLICIE6

SIGNIFICANT ACCOUNTING POLICIES (Details 4) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
	Segment
SIGNIFICANT ACCOUNTING POLICIES	'	'	'
Number of Operating Segments	1	'	'
Uncertain tax positions amount	$0	$0	'
Impairment charges on long-lived assets	$0	$0	$0

PROPERTY_AND_EQUIPMENT_Details

PROPERTY AND EQUIPMENT (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Property and equipment	'	'
Less accumulated depreciation and amortization	($1,276,351)	($553,159)
Property and equipment, net	2,337,210	2,311,942
Computer software and hardware	'	'
Property and equipment	'	'
Gross property and equipment	559,934	362,352
Research and lab equipment	'	'
Property and equipment	'	'
Gross property and equipment	1,881,656	1,448,226
Leasehold improvements	'	'
Property and equipment	'	'
Gross property and equipment	381,225	298,222
Office Equipment	'	'
Property and equipment	'	'
Gross property and equipment	$790,746	$756,301

INTANGIBLE_ASSETS_Details

INTANGIBLE ASSETS (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Amortization	'	'	'
Amortization expense	$17,500	$17,500	$12,500
Future amortization	'	'	'
Expected amortization expense in next year	17,000	'	'
Expected amortization expense in second year	17,000	'	'
Expected amortization expense in third year	17,000	'	'
Expected amortization expense in fourth year	17,000	'	'
Expected amortization expense in fifth year	17,000	'	'
CMCC License	'	'	'
Intangible assets	'	'	'
Useful life	'15 years	'	'
Intangible assets - gross	200,000	200,000	'
Accumulated amortization	-68,861	-51,361	'
Total	$131,139	$148,639	'

ACCRUED_EXPENSES_Details

ACCRUED EXPENSES (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
ACCRUED EXPENSES	'	'
Accrued bonus	$565,489	'
Accrued payroll	101,283	224,596
Deferred rent payable	553,285	310,076
Accrued vacation	23,188	'
Other accrued expenses	48,940	486,603
Accrued expenses, Total	$1,292,185	$1,021,275

NOTE_PAYABLE_Details

NOTE PAYABLE (Details) (USD $)	1 Months Ended
	31-May-13	Dec. 31, 2013
Future minimum principal payments	'	'
2014	'	$73,987
Note Payable	'	'
Note payable	'	'
Cost of purchase of ERP system	150,000	'
Total cost for ERP system including interest	159,000	'
Implicit interest rate	6.00%	'
Future minimum principal payments	'	'
2014	'	73,987
2015	'	18,497
Total	'	$92,484

FAIR_VALUES_OF_ASSETS_AND_LIAB2

FAIR VALUES OF ASSETS AND LIABILITIES (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Assets and liabilities measured at fair value on a recurring basis	'	'	'	'
Derivative warrant liability	$0	$14,584,818	$35,473,230	$10,647,190
Recurring basis	'	'	'	'
Assets and liabilities measured at fair value on a recurring basis	'	'	'	'
Derivative warrant liability	'	14,584,818	'	'
Assets measured at fair value	0	'	'	'
Liabilities measured at fair value	0	'	'	'
Recurring basis | Level 2	'	'	'	'
Assets and liabilities measured at fair value on a recurring basis	'	'	'	'
Derivative warrant liability	'	$14,584,818	'	'

CAPITAL_LEASE_PAYABLE_Details

CAPITAL LEASE PAYABLE (Details) (USD $)	1 Months Ended	12 Months Ended
	Feb. 28, 2011	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Capital lease obligation	'	'	'	'
Less: current portion	'	($2,799)	($32,606)	'
Capital lease obligations Net	'	'	2,799	'
Capital lease information	'	'	'	'
Depreciation expense	'	723,192	349,393	132,162
Assets under capital lease	'	'	'	'
Capital lease obligation	'	'	'	'
Capital lease payable	'	2,799	35,405	'
Less: current portion	'	-2,799	-32,606	'
Capital lease obligations Net	'	'	2,799	'
Capital lease information	'	'	'	'
Value of equipment acquired under capital lease agreement	124,151	'	'	'
Down payment on capital lease agreement	31,000	'	'	'
Monthly installments	2,812	'	'	'
Capital lease payable period	'36 months	'	'	'
Final payment due date	1-Jan-14	'	'	'
Interest expense recorded on the capital lease	'	1,133	3,189	'
Depreciation expense	'	24,831	24,831	22,761
Net book value of capital lease	'	$51,730	$76,559	'

LOAN_PAYABLE_Details

LOAN PAYABLE (Details) (USD $)

12 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Oct. 31, 2012

Sep. 30, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Jun. 30, 2011

Dec. 31, 2013

Dec. 31, 2013

Line of credit

Line of credit

Warrants

MassDev

MassDev

MassDev

MassDev

MassDev

MassDev

MassDev

MassDev

Loan with a bank

Loan with a bank

Loan with a bank

Loan with a bank

Loan with a bank

Loan with a bank

Warrants

Warrants

Equipment Line of Credit

Prime Rate

Warrants

Loan Payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of credit for the purchase of capital equipment

'

'

'

'

$2,000,000

'

'

'

'

'

'

'

'

'

'

$1,000,000

'

'

Line of credit facility commitment fees

'

'

'

'

'

15,000

'

'

'

'

'

'

10,000

'

'

'

'

'

Purchase of common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

16,071

Warrant period

'

'

'

'7 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant exercisable for seven years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1.40

Warrant exercisable for seven years

'

'

'

'

'

'

'

'

'

1.66

'

'

'

'

'

'

'

'

Amortization of the deferred financing costs

'

'

'

'

'

'

'

6,219

4,146

4,560

1,140

'

'

'

'

'

'

'

Interest and debt expense

'

119,817

14,794

'

'

'

'

'

'

'

'

'

'

16,428

8,334

'

'

'

Additional disclosure

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of credit for working capital purpose

'

'

'

'

200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Fixed interest rate (as a percent)

'

'

'

'

'

'

6.50%

'

'

'

'

'

'

'

'

'

'

'

Period for charging 6.5% interest rate

'

'

'

'

'

'

'30 months

'

'

'

'

'

'

'

'

'

'

'

Period for charging equal interest and principal payments

'

'

'

'

'

'

'54 months

'

'

'

'

'

'

'

'

'

'

'

Maturity date

5-Oct-19

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Principal amount outstanding

'

'

'

'

'

'

1,920,000

'

'

'

'

'

'

'

'

'

'

'

Amount of monthly principal payment

'

'

'

'

'

'

35,556

'

'

'

'

'

'

'

'

'

'

'

Commencement date of monthly installments

1-May-15

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Future Principal payment due : 2015

'

'

'

'

'

'

284,444

'

'

'

'

'

'

'

'

'

'

'

Future Principal payment due : 2016

'

'

'

'

'

'

426,667

'

'

'

'

'

'

'

'

'

'

'

Future Principal payment due : 2017

'

'

'

'

'

'

426,667

'

'

'

'

'

'

'

'

'

'

'

Future Principal payment due : 2018

'

'

'

'

'

'

426,667

'

'

'

'

'

'

'

'

'

'

'

Future Principal payment due : 2019

'

'

'

'

'

'

355,555

'

'

'

'

'

'

'

'

'

'

'

Approximate fair value of warrant

'

'

'

'

'

'

'

'

'

31,916

'

'

'

'

'

'

'

10,000

Amortization period of deferred financing cost

'

'

'

'

'

'

'

'

'

'7 years

'

'

'

'

'

'

'

'

Withdrawal for capital equipment

'

'

'

'

'

'

'

'

'

'

'

342,000

'

'

'

'

'

'

Interest rate, minimum (as a percent)

'

'

'

'

'

'

'

'

'

'

'

'

3.50%

'

'

'

'

'

Interest rate, maximum (as a percent)

'

'

'

'

'

'

'

'

'

'

'

'

6.75%

'

'

'

'

'

Variable interest rate base (as a percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'prime rate

'

Loan repayable period

'

'

'

'

'

'

'

'

'

'

'

'

'36 months

'

'

'

'

'

Repayment of loans payable

'

'

'

'

$134,372

'

'

'

'

'

'

'

'

'

'

'

'

'

LOAN_PAYABLE_Detail_2

LOAN PAYABLE (Detail 2) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Summary of loan payable	'	'
Equipment Loan	$1,920,000	$1,578,000
Non current portion of equipment loan	$1,920,000	$1,578,000

INCOME_TAXES_Details

INCOME TAXES (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
Income Taxes	'
Provision or benefit for federal or state income taxes	$0
Expiration of Federal net operating loss carryforwards	'2026
Operating losses carry forward expiration year	'2011
Beginning of expiration research and development tax credit carryforwards	'2021
Research and development	'
Income Taxes	'
Research and development tax credit carryforwards	680,000
Federal	'
Income Taxes	'
Net operating loss carryforwards	41,615,000
Massachusetts	'
Income Taxes	'
Net operating loss carryforwards	$35,656,000

INCOME_TAXES_Details_2

INCOME TAXES (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Significant components of net deferred tax asset	'	'
Net operating loss carryforward	$16,031,911	$10,329,617
Research and development credit carryforward	624,902	329,584
Stock-based compensation	2,411,438	1,090,746
Depreciation and amortization	-148,802	-81,305
Accrued expenses	448,563	'
Charitable contributions	111,776	72,693
Subtotal	19,479,788	11,741,335
Valuation allowance	-19,479,788	-11,741,335
Increase in valuation allowance	7,738,000	4,778,000
Uncertain tax positions	$0	$0

INCOME_TAXES_Details_3

INCOME TAXES (Details 3)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income tax benefits computed using the federal statutory income tax rate	'	'	'
Statutory rate	-34.00%	34.00%	-34.00%
State taxes, net of benefit	-2.60%	-14.20%	-1.40%
Permanent differences:	'	'	'
Derivative losses	17.10%	-127.40%	25.70%
Other	0.00%	-1.90%	0.20%
R&D tax credit	-0.40%	7.00%	-0.20%
Increase in valuation reserve	19.90%	102.50%	9.70%
Effective tax rate	0.00%	0.00%	0.00%

COMMON_STOCK_Details

COMMON STOCK (Details) (USD $)

12 Months Ended

1 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2012

Feb. 29, 2012

Dec. 31, 2011

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Feb. 29, 2012

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2011

Dec. 31, 2010

Warrant One

Public offering

Private placement

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Public offering

Public offering

Private placement

Private placement

Private placement

Common stock, number of shares, par value and other disclosures

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, authorized

200,000,000

200,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, par value (in dollars per share)

$0.00

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, issued

78,773,736

65,881,122

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, outstanding

78,773,736

65,881,122

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock disclosures

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock upon exercise of stock options (in shares)

'

'

'

'

'

'

'

588,884

755,020

143,731

'

'

'

'

'

'

Proceeds from excercise of stock options (in dollars)

$455,550

$112,000

$10,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock upon exercise of warrants (in shares)

'

'

'

'

'

'

734,329

12,224,846

1,779,716

734,329

'

'

'

'

'

'

Proceeds from warrant exercises

15,952,000

'

988,000

1,129,000

'

'

'

'

'

'

'

'

'

'

'

'

Warrants to purchase through cashless exercise provisions (in shares)

'

'

'

1,865,670

'

'

'

627,036

'

'

'

'

'

'

'

'

Warrants to purchase exercise through cash (in shares)

'

'

'

852,946

'

'

'

11,813,334

'

'

'

'

'

'

'

'

Issuance of common stock to 401(k) plan (in shares)

'

'

'

'

'

'

'

78,884

47,105

39,848

'

'

'

'

'

'

Issuance of common stock to 401(k) plan (in dollars)

191,802

91,524

41,662

'

'

'

'

1

'

1

'

'

'

'

'

'

Issuance of stock (in shares)

'

'

'

'

'

'

'

'

'

'

1,095,258

9,523,810

9,523,810

980,392

980,392

12,995,403

Equity issuance, price per share

'

'

'

'

'

'

'

'

'

'

'

$2.10

'

'

'

'

Gross proceeds from issuance of stock (in dollars)

'

'

'

'

20,000,000

'

'

'

'

'

'

'

'

'

'

'

Proceeds from public offering

'

'

'

'

18,155,000

'

'

'

'

'

'

'

'

'

'

'

Proceeds from private placement

'

'

'

'

'

2,000,000

'

'

'

'

'

'

'

'

'

'

Issuance of stock for services (in shares)

'

'

'

'

'

'

'

'

15,000

215,000

'

'

'

'

'

'

Issuance of stock for services (in dollars)

'

$24,750

$209,450

'

'

'

'

'

'

$2

'

'

'

'

'

'

Warrants for purchase of common stock (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

343,137

343,137

'

Exercise price (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

3.06

3.06

'

Tenure of warrant

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'5 years

'

COMMON_STOCK_Details_2

COMMON STOCK (Details 2)	Dec. 31, 2013
Summary of common stock reserves	'
Total Reserves	16,262,331
Warrants	'
Summary of common stock reserves	'
Total Reserves	3,283,134
Stock options	'
Summary of common stock reserves	'
Total Reserves	12,979,197

DERIVATIVE_INSTRUMENTS_Details

DERIVATIVE INSTRUMENTS (Details) (USD $)	3 Months Ended		12 Months Ended
	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Jul. 02, 2012
						item
Derivative Instruments	'	'	'	'	'	'
Redemption of outstanding investor warrants to common stock	11,726,343	'	'	'	'	'
Fair value of investor warrants reclassified from Derivative warrant liability to Additional paid-in capital	$25,241,401	$476,426	$33,456,147	$3,408,738	$1,239,539	'
Number of derivative instruments	'	'	'	'	'	0

DERIVATIVE_INSTRUMENTS_Details1

DERIVATIVE INSTRUMENTS (Details 2) (USD $)	3 Months Ended		12 Months Ended				0 Months Ended
	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	17-May-13	17-May-13	17-May-13
							New Warrants	Merger Warrants	Placement Agent Warrants
Class of Warrant or Right	'	'	'	'	'	'	'	'	'
Extended term of warrant	'	'	'	'	'	'	'2 years	'	'
Warrants to purchase shares of common stock tendered and exchange	'	'	'	'	'	'	'	255,000	3,064,091
Warrants issued	'	'	'	'	'	'	3,319,091	'	'
Incremental fair value from warrant modification	'	'	$764,769	'	'	'	$764,769	'	'
Fair value of derivative warrant liability reclassified to additional paid-in capital	25,241,401	476,426	33,456,147	3,408,738	1,239,539	'	7,738,320	'	'
Derivative instruments, fair value	'	'	0	14,584,818	35,473,230	10,647,190	'	'	'
Warrant derivative loss	'	'	($18,871,329)	$17,479,674	($26,065,579)	'	'	'	'

DERIVATIVE_INSTRUMENTS_Details2

DERIVATIVE INSTRUMENTS (Details 3)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Fair value of warrants	'	'
Expected dividend yield (as a percent)	0.00%	0.00%
Expected volatility (as a percent)	73.00%	79.00%
Maximum	'	'
Fair value of warrants	'	'
Risk-free interest rate (as a percent)	0.35%	0.58%
Contractual term	'2 years 10 months 24 days	'3 years 10 months 24 days
Minimum	'	'
Fair value of warrants	'	'
Risk-free interest rate (as a percent)	0.32%	0.52%
Contractual term	'2 years 8 months 12 days	'3 years 8 months 12 days

DERIVATIVE_INSTRUMENTS_Details3

DERIVATIVE INSTRUMENTS (Details 4) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Changes in derivative warrant liability	'	'	'
Balance at beginning of year	$14,584,818	$35,473,230	$10,647,190
Increase (decrease) in the fair value of the warrants	18,871,329	-17,479,674	26,065,579
Reduction in derivative liability due to exercise of warrants	-33,456,147	-3,408,738	-1,239,539
Balance at end of year	$0	$14,584,818	$35,473,230

STOCK_OPTIONS_Details

STOCK OPTIONS (Details) (USD $)

12 Months Ended

1 Months Ended

8 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Sep. 30, 2011

Apr. 30, 2012

Dec. 31, 2012

Sep. 30, 2011

Dec. 31, 2013

Sep. 30, 2011

Dec. 31, 2013

Restricted stock

Restricted stock

Restricted stock

Vesting Upon FDA clearance of Investigational Device Exemption to permit commencement of human Clinical tria

Vesting Upon FDA clearance of Investigational Device Exemption to permit commencement of human Clinical tria

Vesting Upon FDA clearance of Investigational Device Exemption to permit commencement of human Clinical tria

Vesting Upon FDA Approval of Company biopolymer scaffolding device to treat spinal cord injuries

2007 Plan

2010 Plan

2010 Plan

Stock option

'

'

'

'

'

'

'

'

'

'

'

'

'

Options available to purchase/Common Stock outstanding

8,055,522

8,648,268

'

'

'

'

'

'

'

'

2,198,050

'

5,857,472

Shares available for future grants

'

'

'

'

'

'

'

'

'

'

0

'

4,923,675

Shares authorized for issuance

'

'

'

'

'

'

'

'

'

'

'

'

11,000,000

Exercisable period

'6 years 3 months

'6 years 3 months

'6 years 3 months

'

'

'

'

'

'

'

'10 years

'

'10 years

Stock-based compensation expense, net of forfeitures

'

'

'

$3,135,646

$1,232,959

$921,512

'

'

'

'

'

'

'

Expected term of options granted

'

'

'

'10 years

'

'

'

'

'

'

'

'

'

Vesting period

'5 years 6 months

'

'

'48 months

'

'

'

'

'

'

'

'

'

Restricted stock awards granted

'

'

'

'

'

'

30,000

'

'

50,000

'

80,000

'

Fair value of amortized stock awards

'

'

'

'

'

'

'

23,400

'

'

'

'

'

Expense reversed related to restricted stock awards

'

'

'

'

'

'

'

'

$11,700

'

'

'

'

STOCK_OPTIONS_Details_2

STOCK OPTIONS (Details 2)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Assumptions used principally in determining the fair value of options granted	'	'	'
Expected dividend yield (as a percent)	0.00%	0.00%	0.00%
Expected term (employee grants)	'6 years 3 months	'6 years 3 months	'6 years 3 months
Expected volatility (as a percent)	102.00%	75.00%	49.00%
Minimum	'	'	'
Assumptions used principally in determining the fair value of options granted	'	'	'
Risk-free interest rate (as a percent)	0.77%	0.62%	0.97%
Maximum	'	'	'
Assumptions used principally in determining the fair value of options granted	'	'	'
Risk-free interest rate (as a percent)	2.52%	1.23%	3.05%

STOCK_OPTIONS_Details_3

STOCK OPTIONS (Details 3) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Summary of option activity	'	'	'
Outstanding at the beginning of year (in shares)	8,648,268	'	'
Outstanding at the beginning of year (in dollars per shares)	$1.29	'	'
Granted (in shares)	3,035,000	'	'
Granted (in dollars per shares)	$2.23	'	'
Forfeited (in shares)	-2,902,584	'	'
Forfeited (in dollars per shares)	$1.63	'	'
Exercised (in shares)	-725,162	'	'
Exercised (in dollars per shares)	$0.88	'	'
Outstanding at the end of year (in shares)	8,055,522	8,648,268	'
Outstanding at the end of year (in dollars per shares)	$1.56	$1.29	'
Outstanding at the end of the period	'7 years 6 months 18 days	'	'
Outstanding at the end of the period	$6,704,149	'	'
Vested at the end of period (in shares)	3,661,215	'	'
Vested at the end of period (in dollars per shares)	$0.91	'	'
Vested at the end of period	'5 years 6 months	'	'
Vested at the end of period (in dollars)	5,035,700	'	'
Stock Option	'	'	'
Weighted average grant-date fair value of options granted	$2.04	$1.28	$1.14
Total fair value of options vested	1,985,034	1,186,098	1,324,325
Total unrecognized compensation expense, related to non-vested share-based compensation arrangements	$6,277,267	'	'
Period for unrecognized compensation expense is estimated to be recognized	'3 years 1 month 2 days	'	'

WARRANTS_Details

WARRANTS (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
Warrants to purchase common stock issued and outstanding	'
Number of Warrants	3,283,134
Weighted average exercise price	$1.41
Weighted average life in years	'3 years 7 months 13 days
Equity | Derivative with exercise price one	'
Warrants to purchase common stock issued and outstanding	'
Warrants Issued Year	'2010
Number of Warrants	1,533,163
Warrant Exercise Price	1.4
Equity | Derivative with exercise price one | Maximum	'
Warrants to purchase common stock issued and outstanding	'
Expiration date	3-Dec-17
Equity | Derivative with exercise price one | Minimum	'
Warrants to purchase common stock issued and outstanding	'
Expiration date	26-Oct-17
Equity | Derivative with exercise price two	'
Warrants to purchase common stock issued and outstanding	'
Warrants Issued Year	'2010
Number of Warrants	1,354,618
Warrant Exercise Price	1
Equity | Derivative with exercise price two | Maximum	'
Warrants to purchase common stock issued and outstanding	'
Expiration date	3-Dec-15
Equity | Derivative with exercise price two | Minimum	'
Warrants to purchase common stock issued and outstanding	'
Expiration date	26-Sep-15
Equity | Derivative with exercise price three	'
Warrants to purchase common stock issued and outstanding	'
Warrants Issued Year	'2011
Number of Warrants	16,071
Warrant Exercise Price	1.4
Expiration date	17-Jun-18
Equity | Derivative with exercise price four	'
Warrants to purchase common stock issued and outstanding	'
Warrants Issued Year	'2011
Number of Warrants	343,137
Warrant Exercise Price	3.06
Expiration date	21-Dec-16
Equity | Derivative with exercise price five	'
Warrants to purchase common stock issued and outstanding	'
Warrants Issued Year	'2012
Number of Warrants	36,145
Warrant Exercise Price	1.66
Expiration date	5-Oct-19

EMPLOYEE_BENEFIT_PLAN_Details

EMPLOYEE BENEFIT PLAN (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Employee benefit plan disclosures	'	'	'
Eligibility criteria for participation in the Plan	'21 years	'	'
Fair value of issuance of common stock to 401(k) plan	$191,802	$91,524	$41,662
Common Stock	'	'	'
Employee benefit plan disclosures	'	'	'
Issuance of common stock to 401(k) plan (in shares)	78,884	47,105	39,848
Fair value of issuance of common stock to 401(k) plan	$1	'	$1

INTELLECTUAL_PROPERTY_LICENSE_

INTELLECTUAL PROPERTY LICENSE (Details) (USD $)	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2013
		CMCC License
Intellectual Property License	'	'
Useful life	'	'15 years
Life of license	'	'15-year term, or as long as the life of the last expiring patent right, whichever is longer, unless terminated earlier by the licensor
Intellectual Property License	'	'
Initial license fee paid	$75,000	'
Additional License Fee Paid for expansion	75,000	'
Accrued Milestone payment	$50,000	'

COMMITMENTS_AND_CONTINGENCIES_1

COMMITMENTS AND CONTINGENCIES (Details) (USD $)	Dec. 31, 2013
Future minimum rent commitments	'
2014	$1,202,585
2015	1,242,559
2016	1,268,708
2017	1,294,860
2018	1,049,420
Total	$6,058,132

COMMITMENTS_AND_CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details 2) (USD $)	12 Months Ended				12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Sep. 04, 2013	Dec. 31, 2013	Nov. 30, 2011	Dec. 31, 2013
					Cambridge	Cambridge	Standby letters of credit
						sqft
Commitments and Contingencies	'	'	'	'	'	'	'
Lease Space for Laboratory and office space	'	'	'	'	'	26,150	'
Term of commercial lease	'	'	'	'	'6 years 3 months	'	'
Lease extension option	'	'	'	'	'5 years	'	'
Standby letter of credit	'	'	'	'	'	'	$311,365
Deferred rent liability	'	'	'	'	553,285	'	'
Commitments and Contingencies	'	'	'	'	'	'	'
Leasehold improvements	381,225	'	'	'	'	'	'
Total rent expense	1,125,000	758,000	357,000	'	'	'	'
Amount of legal settlement agreement	'	'	'	$286,000	'	'	'

COMMITMENTS_AND_CONTINGENCIES_3

COMMITMENTS AND CONTINGENCIES (Details 3) (USD $)	1 Months Ended	0 Months Ended
	Nov. 30, 2013	Dec. 06, 2013
	InVivo Therapeutics Holdings Corp. v. Reynolds	Reynolds counterclaim against InVivo Therapeutics Holdings Corp.
		claim
Litigation	'	'
Value of damages sought worth of personal and/or exorbitant expenses	$500,000	'
Number of breach of contract claims	'	2
Number of breach of covenant of good faith and fair-dealing claims	'	2

INSURANCE_CLAIM_Details

INSURANCE CLAIM (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
INSURANCE CLAIM	'
Insurance proceeds from settlement of business interruption claim	$1,100,000